The Role of Sleeve Gastrectomy in Type 2 Diabetes Management

Sleeve gastrectomy is a bariatric surgical procedure that has gained popularity as an effective treatment for obesity and its related comorbidities, including Type 2 diabetes.

The primary goal of this procedure is to promote significant weight loss by reducing the size of the stomach, thus limiting the patient's food intake and inducing hormonal changes that positively impact glucose metabolism [5].

The surgical procedure for sleeve gastrectomy begins with the administration of general anaesthesia, ensuring the patient is completely unconscious and comfortable throughout the operation.

The surgery is typically performed using a laparoscopic approach, which involves making small incisions in the abdomen to insert specialised instruments, including a laparoscope with a camera, to visualise the surgical field [6].

This minimally invasive technique is associated with reduced postoperative pain, faster recovery times, and lower rates of complications compared to open surgery [7].

During the operation, the surgeon removes approximately 75-80% of the stomach, leaving behind a smaller, tubular-shaped stomach that resembles a "sleeve" or "banana" [8].

The greater curvature of the stomach is excised, while the lesser curvature remains intact. This new, smaller stomach has a significantly reduced capacity, which restricts the amount of food a person can consume at one time.

It is important to note that the surgery does not involve any alteration or bypass of the small intestine, as seen in other bariatric procedures such as Roux-en-Y gastric bypass [9].

Despite the numerous benefits associated with sleeve gastrectomy, it is not without potential risks and complications. As with any surgical procedure, there is a risk of infection, bleeding, or adverse reactions to anesthesia.

Moreover, specific risks associated with sleeve gastrectomy include the potential for leaks from the staple line, strictures or narrowing of the sleeve, and gastroesophageal reflux disease (GERD) [10].

Although these complications are relatively rare, it is important for patients and healthcare providers to be aware of the potential risks and make informed decisions regarding the appropriateness of this procedure.

Following sleeve gastrectomy, patients typically experience rapid and substantial weight loss, which has been shown to significantly improve glycemic control in individuals with Type 2 diabetes [3].

Furthermore, the hormonal changes induced by the surgery, such as reduced ghrelin levels and increased incretin secretion, contribute to enhanced insulin sensitivity and glucose metabolism [5].

These combined effects of weight loss and hormonal modulation position sleeve gastrectomy as a promising treatment option for managing Type 2 diabetes, particularly in patients with obesity who have not achieved adequate glycemic control through conventional means.

In summary, sleeve gastrectomy is a bariatric surgical procedure designed to promote weight loss by reducing the size of the stomach. This procedure is performed laparoscopically, offering several advantages over traditional open surgery.

While there are potential risks and complications associated with sleeve gastrectomy, its role in managing Type 2 diabetes has been well-documented in clinical research, showcasing its potential as a viable treatment option for this chronic metabolic disorder.

Sleeve gastrectomy's remarkable impact on Type 2 diabetes management can be attributed to several interconnected mechanisms, which include weight loss, hormonal changes, and improved glucose metabolism.

This section will explore these mechanisms in detail, shedding light on the biological processes that contribute to the procedure's effectiveness in managing Type 2 diabetes.

Weight loss is one of the most significant outcomes of sleeve gastrectomy, and it plays a crucial role in improving insulin resistance in patients with Type 2 diabetes [3].

The substantial reduction in body weight that occurs following the procedure alleviates the burden on the pancreas, allowing it to produce insulin more efficiently.

Additionally, weight loss helps reduce inflammation and oxidative stress, which are both closely linked to insulin resistance [11]. As a result, patients often experience improved glycemic control and reduced dependence on diabetes medications.

Another key factor in sleeve gastrectomy's impact on Type 2 diabetes is the hormonal changes that occur following the surgery. One of the most notable changes is the reduction in ghrelin, a hormone primarily produced by the stomach that stimulates appetite [12].

Sleeve gastrectomy removes a large portion of the stomach, including the area responsible for ghrelin production. Consequently, patients experience a significant decrease in ghrelin levels, which contributes to reduced hunger and food intake.

Lower ghrelin levels have also been associated with increased insulin sensitivity, which further enhances glucose metabolism and glycemic control [13].

In addition to ghrelin, sleeve gastrectomy also affects the production of incretins, gut hormones that play a crucial role in regulating blood sugar levels [14].

The two most well-known incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin secretion in response to food intake and help suppress glucagon production, which in turn reduces hepatic glucose output.

Following sleeve gastrectomy, patients often exhibit increased levels of GLP-1 and GIP, which contribute to enhanced insulin secretion and improved glucose homeostasis [15].

Finally, improved glucose metabolism is a direct result of the combined effects of weight loss and hormonal changes following sleeve gastrectomy. With reduced insulin resistance and enhanced insulin secretion, patients experience better glycemic control, which is essential for managing Type 2 diabetes.

In some cases, the improvements are so significant that patients can achieve normal blood sugar levels without the need for medication [3]. In conclusion, the mechanisms behind sleeve gastrectomy's impact on Type 2 diabetes management are multifaceted and interconnected.

Weight loss, hormonal changes, and improved glucose metabolism all contribute to the procedure's effectiveness in managing this chronic metabolic disorder.

By understanding these mechanisms, healthcare professionals can better appreciate the role of sleeve gastrectomy in Type 2 diabetes management and make more informed decisions regarding the most appropriate treatment strategies for their patients.

A growing body of clinical evidence supports the use of sleeve gastrectomy as an effective treatment for managing Type 2 diabetes. Numerous studies have demonstrated significant improvements in glycemic control, weight loss, and reductions in diabetes medication requirements following the procedure.

This section will discuss some of the key clinical findings that lend support to the role of sleeve gastrectomy in Type 2 diabetes management.

One of the most notable clinical trials investigating the impact of sleeve gastrectomy on Type 2 diabetes is the STAMPEDE trial (Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently) [16].

This randomized controlled trial compared intensive medical therapy alone with intensive medical therapy plus either sleeve gastrectomy or gastric bypass in patients with uncontrolled Type 2 diabetes and a body mass index (BMI) of 27 or higher.

The results demonstrated that at three years, a significantly higher proportion of patients who underwent sleeve gastrectomy (37.5%) achieved the primary outcome (glycated hemoglobin level of 6.0% or lower) compared to those who received intensive medical therapy alone (5.0%).

Additionally, sleeve gastrectomy patients experienced greater weight loss and reductions in diabetes medication requirements. Another important study is the SM-BOSS trial, a randomized clinical trial that compared the effects of sleeve gastrectomy and gastric bypass on weight loss and diabetes remission in morbidly obese patients [9].

The study found that at five years, both surgical procedures resulted in significant and comparable improvements in glycemic control, with 54.1% of sleeve gastrectomy patients and 56.7% of gastric bypass patients achieving diabetes remission.

These results indicate that sleeve gastrectomy is an effective alternative to gastric bypass for the management of Type 2 diabetes in morbidly obese patients. A meta-analysis of 621 studies involving more than 135,000 patients provided further evidence of the benefits of sleeve gastrectomy in Type 2 diabetes management [17].

The analysis demonstrated that overall, 66% of patients who underwent the procedure achieved diabetes remission, defined as a glycated hemoglobin level of 6.0% or lower without the need for diabetes medications.

The authors also noted that patients with a shorter duration of diabetes, lower baseline glycated hemoglobin levels, and greater weight loss were more likely to achieve remission.

Additionally, a study by Lee et al. compared the long-term outcomes of sleeve gastrectomy and gastric bypass in patients with Type 2 diabetes and a BMI of 30 to 35 [18]. The results showed that at five years, both procedures led to significant improvements in glycemic control, with 76.9% of sleeve gastrectomy patients and 85.3% of gastric bypass patients achieving diabetes remission.

The study concluded that sleeve gastrectomy is an effective and durable treatment option for Type 2 diabetes management in patients with a BMI of 30 to 35. In conclusion, the clinical evidence supporting the role of sleeve gastrectomy in Type 2 diabetes management is robust and continues to grow.

These studies demonstrate that sleeve gastrectomy can lead to significant improvements in glycemic control, weight loss, and reductions in diabetes medication requirements, making it an important treatment option for patients with Type 2 diabetes who have not achieved adequate glycemic control through conventional means.

Sleeve gastrectomy can be a highly effective treatment option for managing Type 2 diabetes in select patients.

However, not all patients with Type 2 diabetes are suitable candidates for the procedure.

This section will outline the key criteria that healthcare professionals should consider when evaluating patients for sleeve gastrectomy as a diabetes management strategy.

1. Body Mass Index (BMI): One of the primary criteria for considering sleeve gastrectomy in Type 2 diabetes patients is their BMI. The procedure is typically recommended for patients with a BMI of 35 or higher who have obesity-related comorbidities, such as Type 2 diabetes [1]. However, some studies have demonstrated the effectiveness of sleeve gastrectomy in patients with a lower BMI (30-35) and uncontrolled Type 2 diabetes [18]. Ultimately, the decision to proceed with surgery should be based on a thorough evaluation of the patient's overall health, the severity of their diabetes, and the potential risks and benefits of the procedure.
2. Inadequate Glycemic Control: Sleeve gastrectomy should be considered for patients who have not achieved adequate glycemic control despite optimal medical therapy, including lifestyle modifications, pharmacological interventions, and insulin therapy [3]. In many cases, patients who undergo sleeve gastrectomy experience significant improvements in blood glucose levels, with some achieving diabetes remission.
3. Duration of Diabetes: The duration of diabetes is another important factor to consider when evaluating patients for sleeve gastrectomy. Patients with a shorter duration of diabetes are more likely to achieve remission after the procedure [17]. This may be due to the fact that patients with a longer duration of diabetes typically have more advanced β-cell dysfunction and are less likely to recover normal pancreatic function after surgery [19].
4. Patient Commitment: Sleeve gastrectomy is not a quick fix for Type 2 diabetes management. Patients must be committed to making lifelong lifestyle changes, including adhering to a healthy diet and engaging in regular physical activity, to maintain the benefits of the procedure [20]. It is crucial that healthcare professionals assess the patient's motivation and ability to comply with postoperative care requirements before proceeding with surgery.
5. Age and Comorbidities: While sleeve gastrectomy can be performed safely in most patients, age and the presence of other comorbidities should be considered when evaluating a patient's suitability for the procedure. Older patients and those with significant comorbidities may be at a higher risk for postoperative complications and may require more careful consideration and management [21]. In conclusion, the decision to pursue sleeve gastrectomy as a Type 2 diabetes management strategy should be based on a comprehensive evaluation of the patient's BMI, glycemic control, duration of diabetes, commitment to lifestyle changes, age, and comorbidities.

By carefully considering these criteria, healthcare professionals can help ensure that the most appropriate and effective treatment options are selected for their patients with Type 2 diabetes.

Although sleeve gastrectomy has shown significant promise in the management of Type 2 diabetes, it is essential to acknowledge its limitations and potential concerns.

This section will discuss the potential drawbacks and risks associated with the procedure.

1. Weight Regain: While sleeve gastrectomy often leads to significant weight loss, some patients may experience weight regain in the long-term [22]. Weight regain can result from various factors, including decreased restriction of the gastric pouch, inadequate lifestyle modifications, and hormonal changes. It is crucial that patients adhere to the recommended dietary and lifestyle changes postoperatively to minimize the risk of weight regain and maintain the benefits of the procedure.
2. Surgical Complications: As with any surgery, sleeve gastrectomy carries risks of complications. The most common complications include bleeding, leaks from the staple line, infections, blood clots, and gastrointestinal obstructions [23]. Although the risk of serious complications is relatively low, it is essential to carefully weigh the potential risks and benefits of the procedure and ensure that patients are fully informed about the potential complications.
3. Nutritional Deficiencies: Sleeve gastrectomy may lead to nutritional deficiencies due to the reduced stomach size, which limits the absorption of nutrients [24]. Common deficiencies include vitamin B12, iron, calcium, and vitamin D. Patients who undergo the procedure are typically advised to take lifelong vitamin and mineral supplements and have regular blood tests to monitor their nutrient levels.
4. Limited Impact on Diabetic Complications: While sleeve gastrectomy can improve glycemic control and potentially lead to diabetes remission, it may not reverse existing diabetes-related complications, such as retinopathy, nephropathy, or neuropathy [25]. Patients should continue to receive appropriate care and monitoring for these complications even after undergoing the procedure.
5. Non-Response: Some patients may not experience significant improvements in glycemic control or achieve diabetes remission after undergoing sleeve gastrectomy [26]. The likelihood of a successful outcome may be influenced by factors such as the duration of diabetes, baseline glycated hemoglobin levels, and the degree of weight loss achieved.

It is essential for healthcare professionals to carefully evaluate each patient's individual circumstances and set realistic expectations about the potential outcomes of the procedure. In conclusion, while sleeve gastrectomy can be an effective treatment option for managing Type 2 diabetes in select patients, it is important to consider its limitations and potential concerns.

By carefully weighing the risks and benefits of the procedure, healthcare professionals can help patients make informed decisions about the most appropriate treatment options for their diabetes management.

In conclusion, sleeve gastrectomy has emerged as a promising treatment option for managing Type 2 diabetes in select patients.

The procedure has been shown to lead to significant improvements in glycemic control, weight loss, and reductions in diabetes medication requirements [16, 17].

Moreover, clinical trials such as STAMPEDE and SM-BOSS have demonstrated the efficacy and durability of sleeve gastrectomy in achieving diabetes remission [9, 16].

However, it is crucial to consider the potential limitations and concerns associated with the procedure, such as weight regain, surgical complications, nutritional deficiencies, and limited impact on existing diabetic complications [22-25].

Furthermore, healthcare professionals should carefully evaluate each patient's individual circumstances, including their BMI, glycemic control, duration of diabetes, commitment to lifestyle changes, age, and comorbidities, before recommending sleeve gastrectomy as a diabetes management strategy [1, 3, 18-21].

By thoroughly understanding the benefits, risks, and appropriate patient selection criteria, healthcare professionals can help patients with Type 2 diabetes make informed decisions about the most suitable treatment options for their condition.

As the evidence base continues to grow, sleeve gastrectomy is likely to play an increasingly important role in the management of Type 2 diabetes, offering patients a potentially life-changing intervention to improve their overall health and quality of life.

Sources

1. American Diabetes Association. (2021). Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes. Diabetes Care, 44(Supplement 1), S15–S33. 
2. Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271–281. 
3. Schauer, P. R., Bhatt, D. L., Kirwan,  J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2017). Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. New England Journal of Medicine, 376(7), 641–651.
4. Rosenthal, R. J., International Sleeve Gastrectomy Expert Panel, Diaz, A. A., Arvidsson, D., Baker, R. S., Basso, N., Bellanger, D., Boza, C., El Mourad, H., & France, M. (2012). International Sleeve Gastrectomy Expert Panel Consensus Statement: best practice guidelines based on experience of>12,000 cases. Surgery for Obesity and Related Diseases, 8(1), 8–19. 
5. Rubino, F., & Gagner, M. (2002). Potential of surgery for curing type 2 diabetes mellitus. Annals of Surgery, 236(5), 554–559.
6.  Brethauer, S. A., Hammel, J. P., & Schauer, P. R. (2009). Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surgery for Obesity and Related Diseases, 5(4), 469–475.
7. Zhang, Y., Zhao, H., Cao, Z., Sun, X., Zhang, C., Cai, W., Liu, R., Hu, S., Qin, M., & Yin, P. (2011). A randomized clinical trial of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy for the treatment of morbid obesity in China: a 5-year outcome. Obesity Surgery, 21(10), 1617–1624.
8. Gagner, M., Deitel, M., Erickson, A. L., & Crosby, R. D. (2013). Survey on laparoscopic sleeve gastrectomy (LSG) at the Fourth International Consensus Summit on Sleeve Gastrectomy. Obesity Surgery, 23(12), 2013–2017.
9. Peterli, R., Wölnerhanssen, B. K., Peters, T., Vetter, D., Kröll, D., Borbély, Y., Schultes, B., Beglinger, C., Drewe, J., Schiesser, M., Nett, P., & Bueter, M. (2018). Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA, 319(3), 255–265.
10. Parikh, M., Issa, R., McCrillis, A., Saunders, J. K., Ude-Welcome, A., & Gagner, M. (2013). Surgical strategies that may decrease leak after laparoscopic sleeve gastrectomy: a systematic review and meta-analysis of 9991 cases. Annals of Surgery, 257(2), 231–237.
11. Shoelson, S. E., Lee, J., & Goldfine, A. B. (2006). Inflammation and insulin resistance. Journal of Clinical Investigation, 116(7), 1793–1801.
12. Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002). Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine, 346(21), 1623–1630.
13. Pournaras, D. J., Osborne, A., Hawkins, S. C., Vincent, R. P.,Mahon, D., Ewings, P., Ghatei, M. A., Bloom, S. R., Welbourn, R., le Roux, C. W. (2010). Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2-year outcomes. Annals of Surgery, 252(6), 966–971.
14. Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409–1439.
15. Rubino, F., Forgione, A., Cummings, D. E., Vix, M., Gnuli, D., Mingrone, G., Castagneto, M., & Marescaux, J. (2006). The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Annals of Surgery, 244(5), 741–749.
16.  Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2014). Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. New England Journal of Medicine, 370(21), 2002–2013.
17. Yu, J., Zhou, X., Li, L., Li, S., Tan, J., Li, Y., Sun, X., & Faramand, A. (2015). The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obesity Surgery, 25(1), 143–158.
18.  Lee, W. J., Chong, K., Ser, K. H., Lee, Y. C., Chen, S. C., & Chen, J. C. (2011). Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Archives of Surgery, 146(2), 143–148.
19. Rubino, F., & Gagner, M. (2002). Potential of surgery for curing type 2 diabetes mellitus. Annals of Surgery, 236(5), 554–559.
20.  Kushner, R. F., & Cummings, S. (2014). Bariatric surgery: postoperative nutritional management. In R. F. Kushner & D. H. Bessesen (Eds.), Treatment of the obese patient (pp. 175–190). Springer.
21.  Livingston, E. H., & Ko, C. Y. (2002). Socioeconomic characteristics of the population eligible for obesity surgery. Surgery, 131(3), 354–359.
22. Iannelli, A., Schneck, A. S., & Topart, P. (2013). Laparoscopic sleeve gastrectomy followed by duodenal switch for morbid obesity: the critical points. Journal of Visceral Surgery, 150(5), 351–359.
23.  Aurora, A. R., Khaitan, L., & Saber, A. A. (2012). Sleeve gastrectomy and the risk of leak: a systematic analysis of 4,888 patients. Surgical Endoscopy, 26(6), 1509–1515.
24. Shikora, S. A., Kim, J., & Tarnoff, M. E. (2007). Nutrition and gastrointestinal complications of bariatric surgery. Nutrition in Clinical Practice, 22(1), 29–40.
25. Cummings, D. E., & Rubino, F. (2018). Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia, 61(2), 257–264.
26. Lee, W. J., Chong, K., Chen, J. C